Rats exposed to a cannabinoid agonist during adolescence showed long-lasting changes in brain glucose metabolism during morphine withdrawal in adulthood.
Neuroscientists, addiction researchers, adolescent health specialists, and drug policy researchers.
33M + 32F ratsWistar rats treated with cannabinoid agonist during adolescence (PND 28-38) showed lasting brain changes
What the researchers found
Periadolescent cannabinoid exposure (CP-55,940) produced long-lasting alterations in brain glucose metabolism patterns during morphine withdrawal at 6 and 14 weeks, with sex-dependent differences in affected brain regions.
Why it matters
This study suggests adolescent cannabinoid exposure may permanently alter how the brain responds to opioid withdrawal, with potential implications for understanding gateway drug interactions and vulnerability to opioid addiction.
The numbers in context
Wistar rats (33 males, 32 females) were treated with CP-55,940 from postnatal day 28-38 and underwent morphine withdrawal assessment at PND100.
How the study worked
Preclinical neuroimaging study using PET scanning to measure brain glucose metabolism in rats during morphine withdrawal following adolescent cannabinoid pretreatment.
Who was studied
Wistar rats (33 males, 32 females) with periadolescent cannabinoid exposure assessed during adult morphine withdrawal.
What this study cannot tell us
Animal model findings may not directly translate to humans; CP-55,940 is a synthetic cannabinoid more potent than THC; forced drug administration differs from voluntary human use.
How to read the evidence
Preclinical neuroimaging study with controlled design; animal model limits direct human applicability.
When this study was published
Recent preclinical study with neuroimaging methodology.
The bigger picture
This research contributes to the neurobiological understanding of how early cannabinoid exposure may modify the brains response to other substances, relevant to ongoing debates about cannabis as a gateway drug.
Replication
Adds neuroimaging data to existing behavioral studies on adolescent cannabinoid exposure and opioid interactions.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- Do these metabolic changes translate to behavioral differences in opioid seeking?
- Would natural THC produce similar effects as the synthetic agonist?
- Are the metabolic changes reversible with longer abstinence periods?
Read the original research
Neuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 69, 60-76
Citation
Lamanna-Rama, N; MacDowell, K S; López, G; Leza, J C; Desco, M; Ambrosio, E; Soto-Montenegro, M L. (2023). Neuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 69, 60-76. https://doi.org/10.1016/j.euroneuro.2023.01.005